Skip to main content
Toggle Menu of ADA WebSites
ADA Websites
Partnerships and Commissions
Toggle Search Area
Toggle Menu
e-mail Print Share

Associated Topics

Prevalence of bisphosphonate-related osteonecrosis in patients with cancer could be as high as 13.3 percent

Romesh Nalliah BDS .


Overview

Systematic Review Conclusion

The overall mean weighted prevalence of bisphosphonate-related osteonecrosis (BON) in the evaluated studies was 6.1 percent, and the overall weighted prevalence of BON in studies with documented follow-up was 13.3 percent.

Critical Summary Assessment

There is inconsistency in prevalence study results and a lack of studies in which investigators have evaluated quality-of-life issues related to or the economic effects of BON in patients with cancer.

Evidence Quality Rating

Limited Evidence

This summary is published in the Journal of the American Dental Association and can be accessed at: http://jada.ada.org/article/S0002-8177(14)61038-2/fulltext


Critical Summary Publication Date:

2/1/2012

These summaries are not intended to, and do not, express, imply, or summarize standards of care, but rather provide a concise reference for dentists to aid in understanding and applying evidence from the referenced systematic review in making clinically sound decisions as guided by their clinical judgment and by patient needs. American Dental Association © 2018